AbbVie, Genmab report positive results from Phase III EPCORE DLBCL-2 trial
Phase 3positiveepcoritamabR-CHOPPositive
AI Analysis
Summary
AbbVie and Genmab reported positive Phase III EPCORE DLBCL-2 trial results for epcoritamab combined with R-CHOP in newly diagnosed diffuse large B-cell lymphoma patients. The positive topline data represents a significant development for the candidate therapy.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Positive topline data from Phase III EPCORE DLBCL-2 trial of epcoritamab combined with standard R-CHOP in newly diagnosed DLBCL patients
Importance:8/10
Sentiment:
0.80
Phase 3 trialoncologylymphomaepcoritamabpositive data
Read the original article
Published by Clinical Trials Arena on October 6, 2026 9:28 AM